EFNS guidelines for the diagnosis and management of Alzheimer’s disease

Background and objectives:  In 2008 a task force was set up to develop a revision of the European Federation of the Neurological Societies (EFNS) guideline for the diagnosis and management of Alzheimer’s disease (AD) and other disorders associated with dementia, published in early 2007. The aim of this revised international guideline was to present a peer‐reviewed evidence‐based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with AD. Mild cognitive impairment and non‐Alzheimer dementias are not included in this guideline.

[1]  J. Hodges,et al.  Naming of objects, faces and buildings in mild cognitive impairment , 2008, Cortex.

[2]  L. Thal,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[3]  Roy W Jones,et al.  Safety and tolerability of once‐daily versus twice‐daily memantine: a randomised, double‐blind study in moderate to severe Alzheimer's disease , 2007, International journal of geriatric psychiatry.

[4]  Tim D. Fryer,et al.  Declarative memory impairments in Alzheimer's disease and semantic dementia , 2006, NeuroImage.

[5]  Christine Van Broeckhoven,et al.  Molecular genetics of Alzheimer's disease: An update , 2008, Annals of medicine.

[6]  R. Elble,et al.  Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[7]  R. Tampi,et al.  Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review , 2008, International Psychogeriatrics.

[8]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[9]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[10]  J. Cummings,et al.  Prevalence and impact of medical comorbidity in Alzheimer's disease. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[11]  Lippincott Williams Wilkins,et al.  THERMOREGULATION: RECENT CONCEPTS AND REMAINING QUESTIONS , 2008, Neurology.

[12]  P. Scheltens,et al.  Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe , 2010, European journal of neurology.

[13]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[14]  Guangyu Chen,et al.  Negative Functional Connectivity and Its Dependence on the Shortest Path Length of Positive Network in the Resting-State Human Brain , 2011, Brain Connect..

[15]  P. Bria,et al.  Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study , 2006, European journal of neurology.

[16]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[17]  M. Weiner,et al.  Executive dysfunction in subcortical ischaemic vascular disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[18]  D. Roth,et al.  Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease , 2006, Neurology.

[19]  B. Lawlor,et al.  Use of the Clock Drawing Task in the Diagnosis of Mild and Very Mild Alzheimer's Disease , 1996, International Psychogeriatrics.

[20]  A. Gade,et al.  The Category Cued Recall test in very mild Alzheimer's disease: discriminative validity and correlation with semantic memory functions , 2007, European journal of neurology.

[21]  Douglas Galasko,et al.  Decline in verbal memory during preclinical Alzheimer's disease: Examination of the effect of APOE genotype , 2002, Journal of the International Neuropsychological Society.

[22]  J. O'Brien,et al.  Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology , 2006, Journal of psychopharmacology.

[23]  G Gainotti,et al.  Sensitivity and Specificity of Some Neuropsychological Markers of Alzheimer Dementia , 1998, Alzheimer disease and associated disorders.

[24]  Nick C Fox,et al.  Brain biopsy in dementia. , 2005, Brain : a journal of neurology.

[25]  Y. Nagahama,et al.  The cerebral correlates of different types of perseveration in the Wisconsin Card Sorting Test , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  R. V. Van Heertum,et al.  SPECT perfusion imaging in the diagnosis of Alzheimer’s disease , 2001, Neurology.

[27]  M F Weiner,et al.  A total score for the CERAD neuropsychological battery , 2005, Neurology.

[28]  J. Kowalski,et al.  Evidence-Based Evaluation of Diagnostic Accuracy of Resting EEG in Dementia and Mild Cognitive Impairment , 2009, Clinical EEG and neuroscience.

[29]  S. Graham,et al.  An fMRI study of the Trail Making Test , 2005, Neuropsychologia.

[30]  P. Passmore,et al.  Statins for the prevention of dementia. , 2009, The Cochrane database of systematic reviews.

[31]  B. Dubois,et al.  ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. , 2002, Presse medicale.

[32]  Eric Salmon,et al.  Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer’s disease , 2005, Journal of Neurology.

[33]  W. M. van der Flier,et al.  Associations between Patterns of EEG Abnormalities and Diagnosis in a Large Memory Clinic Cohort , 2008, Dementia and Geriatric Cognitive Disorders.

[34]  N. Tabet,et al.  Vitamin E for Alzheimer's disease and mild cognitive impairment. , 2008, The Cochrane database of systematic reviews.

[35]  C. Xiong,et al.  Reaction to a Dementia Diagnosis in Individuals with Alzheimer's Disease and Mild Cognitive Impairment , 2008, Journal of the American Geriatrics Society.

[36]  Henry Brodaty,et al.  The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta‐analysis of 4 placebo‐controlled clinical trials , 2007, International journal of geriatric psychiatry.

[37]  P. Deyn,et al.  Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone , 2005, Clinical Neurology and Neurosurgery.

[38]  J. Hodges.  Alzheimer's centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. , 2006, Brain : a journal of neurology.

[39]  J. Cummings,et al.  Neuropsychiatric Manifestations in Mild Cognitive Impairment: A Systematic Review of the Literature , 2007, Dementia and Geriatric Cognitive Disorders.

[40]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[41]  T. Dening,et al.  Antidepressants for treating depression in dementia. , 2002, The Cochrane database of systematic reviews.

[42]  J. Wiltfang,et al.  Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease , 2002, Neurology.

[43]  L. Flicker,et al.  Selegiline for Alzheimer's disease. , 2003, The Cochrane database of systematic reviews.

[44]  Sönke Arlt,et al.  Detecting depression in Alzheimer's disease: evaluation of four different scales. , 2005, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[45]  I. McKeith,et al.  Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study , 2007, The Lancet Neurology.

[46]  K. Heilman,et al.  Ecological implications of ideomotor apraxia: Evidence from physical activities of daily living , 2003 .

[47]  L. Flicker,et al.  Piracetam for dementia or cognitive impairment. , 2004, The Cochrane database of systematic reviews.

[48]  D. Schubert,et al.  Presenilin-interacting proteins , 2002, Expert Reviews in Molecular Medicine.

[49]  John R Hodges,et al.  The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.

[50]  Manjit,et al.  Neurology , 1912, NeuroImage.

[51]  Joost Dekker,et al.  Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study , 2008, BMJ : British Medical Journal.

[52]  J. Olin,et al.  Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. , 2008, Current Alzheimer research.

[53]  L. Thorpe,et al.  Assessment of Behavioural and Psychological Symptoms Associated with Dementia , 2007, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[54]  P. Scheltens,et al.  Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline , 2007, European journal of neurology.

[55]  R Brookmeyer,et al.  Visual memory predicts Alzheimer’s disease more than a decade before diagnosis , 2003, Neurology.

[56]  Nicola Vanacore,et al.  Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials , 2007, PLoS medicine.

[57]  F. Verhey,et al.  The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[58]  S. E. Black,et al.  Donepezil preserves cognition and global function in patients with severe Alzheimer disease , 2007, Neurology.

[59]  C. Bulpitt,et al.  Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial , 2008, The Lancet Neurology.

[60]  L. Thal,et al.  Alzheimer’s disease can be accurately diagnosed in very mildly impaired individuals , 2002, Neurology.

[61]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[62]  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study , 2004 .

[63]  Mary Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[64]  M. Brainin,et al.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004 * , 2004, European journal of neurology.

[65]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[66]  Kelvin Lam,et al.  Antipsychotic Drug Use and Mortality in Older Adults with Dementia , 2007, Annals of Internal Medicine.

[67]  S. Gauthier,et al.  Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis , 2008, International journal of geriatric psychiatry.

[68]  Frederik Barkhof,et al.  Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion , 2002, The Lancet Neurology.

[69]  R J Harvey,et al.  Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.

[70]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[71]  A. Wallen,et al.  A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[72]  J. Rusted,et al.  Vitamin E for Alzheimer's dementia and mild cognitive impairment. , 2012, The Cochrane database of systematic reviews.

[73]  Abass Alavi,et al.  PET imaging in the assessment of normal and impaired cognitive function. , 2005, Radiologic clinics of North America.

[74]  M. Farlow.  The search for disease modification in moderate to severe Alzheimer disease , 2005, Neurology.

[75]  R. Petersen,et al.  Detecting dementia with the mini-mental state examination in highly educated individuals. , 2008, Archives of neurology.

[76]  A. Tibben.  Predictive testing for Huntington's disease , 2007, Brain Research Bulletin.

[77]  D. Salmon,et al.  Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease , 2008, Journal of the International Neuropsychological Society.

[78]  J. O'Brien,et al.  Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology , 2011, Journal of psychopharmacology.

[79]  P. Panegyres,et al.  Fluorodeoxyglucose-Positron Emission Tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study , 2009, BMC neurology.

[80]  T. Wisniewski,et al.  Amyloid-β immunisation for Alzheimer's disease , 2008, The Lancet Neurology.

[81]  J. Birks,et al.  Ginkgo biloba for cognitive impairment and dementia. , 2007, The Cochrane database of systematic reviews.

[82]  M. Oremus,et al.  Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Behavior and Mood Scales , 2000, Journal of geriatric psychiatry and neurology.

[83]  K. Hess,et al.  CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease , 2006, Neurology.

[84]  Martin Klein,et al.  Precuneus atrophy in early-onset Alzheimer’s disease: a morphometric structural MRI study , 2007, Neuroradiology.

[85]  D. Coakley,et al.  The utility of naming tests in the diagnosis of Alzheimer's disease , 1999, Irish Journal of Psychological Medicine.

[86]  G. Frisoni,et al.  Consistency of Neuropsychiatric Syndromes across Dementias: Results from the European Alzheimer Disease Consortium , 2007, Dementia and Geriatric Cognitive Disorders.

[87]  T. J. Grabowski,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease , 2008 .

[88]  W. Bouman,et al.  Attitudes of Patients With Mild Dementia and Their Carers Towards Disclosure of the Diagnosis , 2003, International Psychogeriatrics.

[89]  Lewis H Kuller,et al.  Ginkgo biloba for prevention of dementia: a randomized controlled trial. , 2008, JAMA.

[90]  Alan J. Thomas,et al.  A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. , 2004, The Journal of clinical psychiatry.

[91]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[92]  W. M. van der Flier,et al.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.

[93]  P. Tariot,et al.  Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. , 1998, The American journal of psychiatry.

[94]  A. Wimo,et al.  Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial , 2009, The Lancet Neurology.

[95]  Martin Knapp,et al.  Donepezil for the treatment of agitation in Alzheimer's disease. , 2007, The New England journal of medicine.

[96]  Philip Scheltens,et al.  Imaging in Alzheimer's disease , 2009, Dialogues in clinical neuroscience.

[97]  Z-h Wei,et al.  Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease , 2007, Journal of Neural Transmission.

[98]  O. Napryeyenko,et al.  Ginkgo biloba Special Extract in Dementia with Neuropsychiatric Features , 2007, Arzneimittelforschung.

[99]  W. M. van der Flier,et al.  Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. , 2009, Radiology.

[100]  J T O'Brien,et al.  Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. , 2009, Brain : a journal of neurology.

[101]  C. Kawas,et al.  Sensitivity and Specificity of the Mini‐Mental State Examination for Identifying Dementia in the Oldest‐Old: The 90+ Study , 2007, Journal of the American Geriatrics Society.

[102]  P. Scheltens,et al.  A systematic review of Instrumental Activities of Daily Living scales in dementia: room for improvement , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.